IL-13 Inhibitor — Atopic Eczema Pregnancy: US labelling (section 8.1): available data in pregnant women are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage or other adverse outcomes. Monoclonal antibodies are actively transported across the placenta, so the drug may be present in infants exposed in utero (greatest transfer in the third trimester). No effects on embryo-foetal development in cynomolgus monkeys at doses up to 18 times the human exposure at the maximum recommended human dose.

Lebrikizumab

Brand names: Ebglyss

Lebrikizumab is a monoclonal antibody biologic given by subcutaneous injection for moderate-to-severe atopic dermatitis (eczema) in adults and adolescents.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 500 mg (two 250 mg injections) at Week 0 and at Week 2, followed by 250 mg (one injection) every 2 weeks until Week 16 or later, when adequate clinical response is achieved; maintenance 250 mg every 4 weeks or 250 mg every 8 weeks

Route: Subcutaneous injection

Frequency: 500 mg at Weeks 0 and 2, then 250 mg every 2 weeks to Week 16 or later; then 250 mg every 4 weeks or every 8 weeks as maintenance

Taken from the US prescribing information (EBGLYSS, moderate-to-severe atopic dermatitis) — no UK SPC posology was present in the fetched bundle, so verify against the UK SPC before use. Complete all age-appropriate vaccinations according to current immunisation guidelines prior to starting treatment. May be used with or without topical corticosteroids; topical calcineurin inhibitors may be used but reserved for sensitive areas only (face, neck, intertriginous and genital areas). Missed dose: administer as soon as possible, then resume dosing at the regular scheduled time. Paediatric: safety and effectiveness are established in patients 12 years and older weighing at least 40 kg (US label states no separate per-kg or reduced dose for this group); not established below 12 years or in patients 12 years and older weighing less than 40 kg. Intended for use under the guidance of a healthcare professional; adults may self-inject and caregivers may inject after training. Injection sites: abdomen, thigh and back of upper arm (upper arm by caregiver or healthcare provider); alternate sites, do not inject within 5 cm (2 inches) of the navel or into skin that is tender, bruised, red, hard, or affected by atopic dermatitis or skin lesions. Available as 250 mg/2 mL single-dose prefilled pen and 250 mg/2 mL (125 mg/mL) single-dose prefilled syringe.

Dose auto-extracted from US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

Prior serious hypersensitivity to lebrikizumab-lbkz or any of the excipients

Side effects

Conjunctivitis (most frequently reported eye disorder; more frequent than placebo)
Injection site reactions
Herpes zoster
Keratitis
Hypersensitivity reactions including angioedema and urticaria

Interactions

Live vaccines — avoid use during treatment; complete all age-appropriate vaccinations before initiating (US label section 5.4). No dedicated drug interaction section was present in the fetched source.

Clinical monograph

How it works

It binds interleukin-13 and prevents its signalling, dampening the type 2 inflammation responsible for the skin barrier dysfunction, itch and inflammation of atopic dermatitis.

Prescribing in practice

Conjunctivitis is a recognised class-related adverse effect; advise patients to report new or persistent eye symptoms.
Assess for active infection before starting and avoid live vaccines during treatment.
It may be used with or without topical corticosteroids and is given by subcutaneous injection.

Monitoring

Monitoring is predominantly clinical, assessing eczema severity and itch response and reviewing for conjunctivitis or other ocular symptoms.

Counselling the patient

Report red, sore or gritty eyes, as conjunctivitis can occur with this medicine.
You may continue your usual emollients and may still need topical treatments for flares.
Improvement in itch and skin appearance builds over several weeks of regular dosing.

Evidence & guidelines

Lebrikizumab's efficacy in atopic dermatitis was shown in the ADvocate phase 3 trials, and it is appraised by NICE for moderate-to-severe disease.

Reference: ADvocate-1 Trial (Silverberg et al. NEJM 2023); ADhere Trial; NICE TA981; SPC Ebglyss; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Drugs

Tralokinumab · IL-13 Inhibitor — Atopic Eczema

Pathways